Next Article in Journal
The Search for Biomarkers in Fibromyalgia
Next Article in Special Issue
Comparison of Ki-67 Labeling Index Patterns of Diffuse Large B-Cell Lymphomas and Burkitt Lymphomas Using Image Analysis: A Multicenter Study
Previous Article in Journal
Atypical Cellular Elements of Unknown Origin in the Subbasal Nerve Plexus of a Diabetic Cornea Diagnosed by Large-Area Confocal Laser Scanning Microscopy
Previous Article in Special Issue
Biomarkers for Inner Ear Disorders: Scoping Review on the Role of Biomarkers in Hearing and Balance Disorders
Open AccessArticle

Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC

Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Ludmilla Morozova-Roche
Diagnostics 2021, 11(2), 155; https://doi.org/10.3390/diagnostics11020155
Received: 29 December 2020 / Revised: 18 January 2021 / Accepted: 19 January 2021 / Published: 21 January 2021
(This article belongs to the Collection Biomarkers in Medicine)
Liquid biopsy tests have become an integral part of the molecular diagnosis of patients with non-small cell lung cancer (NSCLC). We describe a new test panel that uses very low input (20 ng) of cell-free nucleic acids extracted from human plasma, which is designed to yield results in less than 72 h. In this study, we performed novel amplicon-based targeted next-generation sequencing with a semiconductor-based system, the Ion GeneStudio S5 Prime. The analytic performance of the assay was evaluated using contrived and retrospectively collected clinical specimens. The cumulative percent coefficient of variation for the new test process was very precise at 8.4% for inter-day, 4.0% for inter-operator and 3.4% for inter-instrument. We also observed significant agreement (95.7–100%) with an orthogonal, high-sensitivity droplet digital™ Polymerase Chain Reaction (ddPCR) test. This method offers a valuable supplement to assessing targeted mutations from blood while conserving specimens and maintaining sensitivity, with rapid turn-around times to actionable results. View Full-Text
Keywords: diagnostics; non-small cell lung cancer (NSCLC); liquid biopsy; next generation sequencing (NGS) diagnostics; non-small cell lung cancer (NSCLC); liquid biopsy; next generation sequencing (NGS)
Show Figures

Figure 1

MDPI and ACS Style

Mellert, H.; Reese, J.; Jackson, L.; Maxwell, V.; Tschida, C.; Pestano, G.A. Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC. Diagnostics 2021, 11, 155. https://doi.org/10.3390/diagnostics11020155

AMA Style

Mellert H, Reese J, Jackson L, Maxwell V, Tschida C, Pestano GA. Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC. Diagnostics. 2021; 11(2):155. https://doi.org/10.3390/diagnostics11020155

Chicago/Turabian Style

Mellert, Hestia; Reese, Jordan; Jackson, Leisa; Maxwell, Victoria; Tschida, Chérie; Pestano, Gary A. 2021. "Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC" Diagnostics 11, no. 2: 155. https://doi.org/10.3390/diagnostics11020155

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop